Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: A clinical case study

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1155-1160

  Morrow, C J ^a,f   Trapani, F ^a   Metcalf, R L ^a   Bertolini, G ^b   Hodgkinson, C L ^a   Khandelwal, G ^a   Kelly, P ^a   Galvin, M ^a   Carter, L ^a   Simpson, K L ^a   Williamson, S ^a   Wirth, C ^c   Simms, N ^a   Frankliln, L ^a   Frese, K K ^a   Rothwell, D G ^a   Nonaka, D ^d   Miller, C J ^a   Brady, G ^a   F H Blackhall, ^a,d,e   Dive, C ^a,e   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e University of Manchester and University College London   (United Kingdom)

^f CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Circulating tumour cells; Epithelial to mesenchymal transition (EMT); Non small cell lung cancer; Patient derived circulating tumour cells explants (CDX); Preclinical therapeutics

Indexed keywords

CISPLATIN; CK7 PROTEIN; PEMETREXED; RNA; TTF1 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; VIMENTIN; DNA BINDING PROTEIN; TRANSCRIPTION FACTOR; TTF1 PROTEIN, HUMAN;

ADULT; ALK GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENETICS; CANCER TRANSPLANTATION; CARCINOGENESIS; CASE REPORT; CIRCULATING TUMOR CELL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; EGFR GENE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYME CELL; METASTASIS; MIDDLE AGED; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SOMATIC MUTATION; ANIMAL; CANCER STEM CELL; DRUG EFFECTS; DRUG SCREENING; GENETICS; MESENCHYMAL STROMA CELL; MUTATION; PATHOLOGY; TUMOR EMBOLISM;

ANIMALS; BIOMARKERS, TUMOR; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA-BINDING PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MUTATION; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PEMETREXED; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84974824198     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw122     Document Type: Article

References (15)

1. Krebs MG, Metcalf RL, Carter L et al. Molecular analysis of circulating tumour cellsbiology and biomarkers. Nat Rev Clin Oncol 2014; 11: 129-144.
2. Hodgkinson CL, Morrow CJ, Li Y et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014; 20: 897-903.
3. Baccelli I, Schneeweiss A, Riethdorf S et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539-544.
4. Yu M, Bardia A, Aceto N et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014; 345: 216-220.
5. Krebs MG, Sloane R, Priest L et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011; 29: 1556-1563.
6. Krebs MG, Hou JM, Sloane R et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 2012; 7: 306-315.
7. Hou JM, Krebs M, Ward T et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 2011; 178: 989-996.
8. Lecharpentier A, Vielh P, Perez-Moreno P et al. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic nonsmall cell lung cancer. Br J Cancer 2011; 105: 1338-1341.
9. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714.
10. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
11. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
12. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-6309.
13. Khoja L, Backen A, Sloane R et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer 2012; 106: 508-516.
14. Byers LA, Diao L, Wang J et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013; 19: 279-290.
15. Hidalgo M, Amant F, Biankin AV et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014; 4: 998-1013.